Company news
Neovasc Inc news in 2018
Neovasc Inc's news releases, calls and decks from 2018, newest first.
Neovasc Receives ISO 13485: 2016 Certification
December 21, 2018
Neovasc Announces Positive 12-year Follow-up Data for Neovasc Reducer(TM) as Published in JACC
December 11, 2018
JACC: Cardiovascular Interventions Publishes Peer Reviewed Article on Neovasc Reducer(TM) Patient Case
November 20, 2018
Neovasc Announces Third Quarter 2018 Financial Results
November 14, 2018
Neovasc Announces Third Quarter 2018 Financial Results Conference Call and Webcast
November 7, 2018
Neovasc Announces Successful Tiara(TM) "Live Case" at the 32nd Annual EACTS 2018 Meeting
October 22, 2018
Neovasc Announces Publication of a Peer-Reviewed Article on Tiara(TM) Cases in Circulation: Cardiovascular Interventions
October 16, 2018
Neovasc Reducer(TM) Granted Breakthrough Device Designation from FDA
October 10, 2018
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
October 9, 2018
Neovasc Announces Positive 12-week Follow-up Data from the First U.S. Patient Implanted with a Neovasc Reducer(TM)
October 3, 2018
Neovasc's Tiara and Reducer to be Featured at TCT 2018 Conference
September 20, 2018
Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany
September 19, 2018
Neovasc Announces Effective Date of Share Consolidation
September 18, 2018
Neovasc Announces Amendments to Outstanding Convertible Notes, including 1-Year Extension of Note Maturity Date
September 12, 2018
Neovasc Announces Second Quarter 2018 Financial Results
August 8, 2018
Neovasc Announces Updated Presentation Time at the 38th Annual Canaccord Genuity Growth Conference
August 8, 2018
Neovasc Announces Publication of Safety and Efficacy Results from REDUCE Study in International Journal of Cardiology
August 6, 2018
Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference
August 6, 2018
Neovasc Announces Collaboration and Licensing Agreement with Penn Medicine and the Gorman Cardiovascular Research Group
August 3, 2018
Neovasc Announces Second Quarter 2018 Financial Results Conference Call and Webcast
August 2, 2018
Nasdaq Schedules Hearing to Consider Neovasc's Appeal of Delisting Determination
July 16, 2018
Neovasc Announces Filing of "Administrative" Prospectus Supplement Relating to Expiry of Prior Shelf Prospectus / Registration Statement
July 16, 2018
Neovasc Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing
July 9, 2018
Tiara and Reducer Featured at CSI Frankfurt 2018
July 2, 2018
Neovasc Announces Filing of Shelf Prospectus and Form F-10 Registration Statement
July 2, 2018
Tiara(TM) Featured in Live Case at 11th Annual TVT 2018
June 21, 2018
Neovasc Announces First Implant of a Neovasc Reducer(TM) in a U.S. Patient
June 20, 2018
Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update
June 11, 2018
Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders
June 4, 2018
Neovasc Provides Highlights from EuroPCR; Symposium Generates Increased Interest in Reducer
May 25, 2018
Neovasc's Management and Board of Directors Urge Shareholders to Vote In Favor of the Proposed Reverse Stock Split at the Upcoming Annual General and Special Meeting of Shareholders
May 15, 2018
Neovasc Announces Results for the First Quarter 2018
May 10, 2018
Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule
May 10, 2018
Neovasc Provides a General Update, Announces Filing of Annual Report on Form 20-F and Sets First Quarter 2018 Financial Results Conference Call and Webcast
April 30, 2018
Neovasc Announces Receipt of US$7.1 Million from Exercise of Series C Warrants
April 11, 2018
Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2017
March 28, 2018
Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
March 23, 2018
Neovasc Announces Year End 2017 Financial Results Conference Call and Webcast
March 21, 2018